source: amrismartsourcing.com |
Early phase I and phase II clinical trials with small numbers of subjects were promising. Based on these results, the company conducted larger phase III trials, called the FORWARD (Focused On Results With A Rethinking of Depression) trials. Unfortunately, the first two of the larger trials failed, showing no improvement over placebo. The third trial (FORWARD-5) was more successful. In that trial, 407 patients with depression unresponsive to a trial of standard antidepressants were randomized to receive ALKS 5461 as an adjunct, or placebo as an adjunct. The company reports that patients receiving the higher dose of 2mg of ALKS 5461 did significantly better than placebo, as measured by the MADRS rating scale. Side effects were nausea, dizziness, and fatigue.
Will this drug see the light of day? It’s unclear, but according to pharmaceutical industry news sources, Alkermes has been talking up its latest results with the FDA and hopes to get approval at some point within a year or two. It sure would be nice to have another antidepressant at our disposal.
2 comments:
Hi Dr. Carlat,
Greetings from Boston. I am glad to see new posts from you, and also talk about the mu opioid receptor as a novel antidepressant target. I have a clinical diagnosis of PTSD and bipolar. After years of unsuccessful therapy on various combos of SSRIs, antipsychotics, benzos, and mood stabilizers, I have finally found relief with a TCA not marketed in the US called tianeptine. Although an old drug, tianeptine has recently been shown to have affinity for the mu opioid receptor.
My hope is that more and more research like this (along with the recent ketamine studies) will shift focus away from monoamine reuptake in antidepressant drug design.
Regards,
Matt
Wow, the road to hell paved again with a premise of good intentions, but, once the fourth "P" of poison comes out from the process of pharmacology (the other three in order being promise, panacea, and placebo), what did Einstein warn us again about the true meaning of insanity?...
Well, at least then psychiatrists can be prescribing opiates without being accused of writing scripts out of their specialty, a silver lining there?!
Joel Hassman, MD
Post a Comment